The modification to the drug results in a 1,000-fold increase to its antibiotic activity and works against the bacteria in three ways to make the development of drug-resistance more difficult.
“This increases the durability of this antibiotic,” said Dale Boger, co-chair of the La Jolla, Calif.-based Scripps Research Institute’s chemistry department and one of the study’s researchers, according to CNN. “Organisms just can’t simultaneously work to find a way around three independent mechanisms of action. Even if they found a solution to one of those, the organisms would still be killed by the other two.”
Enterococci bacteria can cause dangerous urinary and surgical wound infections. It could potentially take years before the revamped antibiotic clears the necessary clinic trials to become mass-produced antibiotic therapy.
To learn more about Enterococci bacteria, click here.
To read the full study, click here.
More articles infection control:
Hot or cool: Water temperature does not impact bacteria removal during hand washing, study shows
To up patient compliance with hand hygiene, consider ease of use, study says
What happens when a hospital NICU goes handshake-free?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.